Helen Torley Sells 10,000 Shares of Halozyme Therapeutics (NASDAQ:HALO) Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) CEO Helen Torley sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $69.19, for a total transaction of $691,900.00. Following the sale, the chief executive officer owned 767,780 shares of the company’s stock, valued at approximately $53,122,698.20. This represents a 1.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Helen Torley also recently made the following trade(s):

• On Tuesday, May 12th, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $71.75, for a total transaction of $1,435,000.00.
• On Monday, April 6th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $63.50, for a total transaction of $635,000.00.
• On Thursday, April 2nd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $64.24, for a total transaction of $1,284,800.00.
• On Wednesday, March 4th, Helen Torley sold 10,000 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $70.21, for a total transaction of $702,100.00.
• On Monday, March 2nd, Helen Torley sold 20,000 shares of Halozyme Therapeutics stock. The shares were sold at an average price of $69.69, for a total value of $1,393,800.00.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ HALO opened at $69.21 on Friday. The business’s 50-day moving average price is $65.70 and its two-hundred day moving average price is $68.65. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 3.66. Halozyme Therapeutics, Inc. has a one year low of $47.74 and a one year high of $82.22. The company has a market capitalization of $8.21 billion, a P/E ratio of 24.90, a price-to-earnings-growth ratio of 0.29 and a beta of 0.89.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.06. The company had revenue of $376.71 million during the quarter, compared to the consensus estimate of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The business’s quarterly revenue was up 42.2% on a year-over-year basis. During the same period last year, the business earned $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Analysts anticipate that Halozyme Therapeutics, Inc. will post 7.68 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have commented on the stock. Wells Fargo & Company boosted their target price on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 19th. Wall Street Zen lowered shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Saturday, February 21st. Benchmark increased their target price on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. HC Wainwright raised their target price on Halozyme Therapeutics from $90.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Finally, Weiss Ratings raised Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday. Seven research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $80.67.

Institutional Trading of Halozyme Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Epoch Investment Partners Inc. grew its holdings in Halozyme Therapeutics by 113.4% in the 1st quarter. Epoch Investment Partners Inc. now owns 1,138,377 shares of the biopharmaceutical company’s stock valued at $73,573,000 after buying an additional 605,018 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Halozyme Therapeutics by 30.1% during the first quarter. Renaissance Technologies LLC now owns 731,811 shares of the biopharmaceutical company’s stock worth $47,297,000 after buying an additional 169,100 shares during the last quarter. Inceptionr LLC acquired a new position in shares of Halozyme Therapeutics during the first quarter worth approximately $771,000. Mizuho Markets Americas LLC boosted its position in shares of Halozyme Therapeutics by 4.3% in the first quarter. Mizuho Markets Americas LLC now owns 1,323,544 shares of the biopharmaceutical company’s stock valued at $85,541,000 after acquiring an additional 54,871 shares during the period. Finally, Gibbs Wealth Management boosted its position in shares of Halozyme Therapeutics by 191.8% in the first quarter. Gibbs Wealth Management now owns 9,049 shares of the biopharmaceutical company’s stock valued at $585,000 after acquiring an additional 5,948 shares during the period. Institutional investors own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.